University Hospitals Birmingham NHS Trust
Kyowa Kirin and University Hospitals Birmingham announce new survival data in rare disease study
The study demonstrated meaningful survival benefits for patients with cutaneous T cell lymphoma
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis
The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide
SMC enables access to Kyowa Kirin’s Crysvita for adults with rare genetic disease
XLH is a life-long genetic disease that causes abnormalities in the bones, muscles and joints
CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
Results of eight main studies of drug were 'inconsistent', according to the CHMP
SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease
Drug is being reviewed under new ultra-orphan pathway
NICE U-turn on Crystiva for rare bone disease
Watchdog to back the drug to treat young people with XLH
FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo
Becomes the first drug approved to treat Sézary syndrome
NICE set to reject Kyowa Kirin’s Crysvita for XLH
Committee says the rare disease therapy isn’t value for money